Wave Net Income Per E B T from 2010 to 2025

WVE Stock  USD 10.35  0.22  2.08%   
Wave Life's Net Income Per E B T is decreasing over the years with very volatile fluctuation. Net Income Per E B T is expected to dwindle to 0.79. During the period from 2010 to 2025 Wave Life Net Income Per E B T annual values regression line had geometric mean of  0.95 and mean square error of  0. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
0.89
Current Value
0.79
Quarterly Volatility
0.06397558
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Wave Life financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Wave Life's main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.1 M, Interest Expense of 1.8 M or Selling General Administrative of 36.3 M, as well as many indicators such as Price To Sales Ratio of 15.0, Dividend Yield of 0.0 or PTB Ratio of 15.68. Wave financial statements analysis is a perfect complement when working with Wave Life Valuation or Volatility modules.
  
Check out the analysis of Wave Life Correlation against competitors.

Latest Wave Life's Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of Wave Life Sciences over the last few years. It is Wave Life's Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Wave Life's overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Very volatile
   Net Income Per E B T   
1.021.001.010.930.990.890.79-2%1%-8%6%-10%-11%100%
       Timeline  

Wave Net Income Per E B T Regression Statistics

Arithmetic Mean0.95
Geometric Mean0.95
Coefficient Of Variation6.70
Mean Deviation0.05
Median0.99
Standard Deviation0.06
Sample Variance0
Range0.2263
R-Value(0.08)
Mean Square Error0
R-Squared0.01
Significance0.76
Slope(0)
Total Sum of Squares0.06

Wave Net Income Per E B T History

2025 0.79
2024 0.89
2020 0.99
2019 0.93
2016 1.01
2015 1.0
2014 1.02

About Wave Life Financial Statements

Wave Life stakeholders use historical fundamental indicators, such as Wave Life's Net Income Per E B T, to determine how well the company is positioned to perform in the future. Although Wave Life investors may analyze each financial statement separately, they are all interrelated. For example, changes in Wave Life's assets and liabilities are reflected in the revenues and expenses on Wave Life's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Wave Life Sciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per E B T 0.89  0.79 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Wave Life Sciences is a strong investment it is important to analyze Wave Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Wave Life's future performance. For an informed investment choice regarding Wave Stock, refer to the following important reports:
Check out the analysis of Wave Life Correlation against competitors.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Wave Life. If investors know Wave will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Wave Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.70)
Revenue Per Share
0.783
Quarterly Revenue Growth
1.882
Return On Assets
(0.22)
Return On Equity
(0.73)
The market value of Wave Life Sciences is measured differently than its book value, which is the value of Wave that is recorded on the company's balance sheet. Investors also form their own opinion of Wave Life's value that differs from its market value or its book value, called intrinsic value, which is Wave Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Wave Life's market value can be influenced by many factors that don't directly affect Wave Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Wave Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Wave Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Wave Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

ABOS
Acumen Pharmaceuticals
1.22  -0.01  -0.81 
ALNY
Alnylam Pharmaceuticals
246.89  -2.34  -0.94 
ARWR
Arrowhead Pharmaceuticals
17.21  -0.14  -0.81 
PRQR
ProQR Therapeutics
1.91  -0.13  -6.37 
XFOR
X4 Pharmaceuticals
0.37  -0.0006  -0.16 
CTMX
CytomX Therapeutics
0.61  -0.01  -2.39 
AMLX
Amylyx Pharmaceuticals
3.61  0.60  19.93 
INZY
Inozyme Pharma
1.22  0.03  2.52 
BPMC
Blueprint Medicines Corp
87.38  -2.54  -2.82 
DAWN
Day One Biopharmaceu
9.09  -0.61  -6.29 
ASMB
Assembly Biosciences
11.68  -0.3  -2.5 
MREO
Mereo BioPharma Group
2.44  -0.09  -3.56 
APLS
Apellis Pharmaceuticals
25.27  -0.73  -2.81 
TERN
Terns Pharmaceuticals
3.63  0.12  3.42 
VECT
VectivBio Holding
0.00  0.00  0.00 
ICVX
Icosavax
0.00  0.00  0.00 
NLTX
Neoleukin Therapeutics
0.00  0.00  0.00 
ITOS
Iteos Therapeutics
7.03  -0.23  -3.17 
TCRX
Tscan Therapeutics
1.97  0.05  2.60 
News Freq…Investor S…